论文部分内容阅读
目的:探讨雷贝拉唑、克拉霉素、阿莫西林、胶体铋剂四联治疗幽门螺杆菌感染慢性胃炎的治疗效果。方法:选取2014年11月至2015年11月在我院消化内科收治的幽门螺杆菌感染慢性胃炎的患者143例。并随机分成观察组(A组)47例患者、对照组(B组)48例患者、对照组(C组)48例患者。观察组(A组)给予雷贝拉唑、克拉霉素、阿莫西林、胶体铋剂四联治疗;对照组(B组)给予胶体铋剂、克拉霉素、阿莫西林三联治疗;对照组(C组)给予雷贝拉唑、克拉霉素、阿莫西林三联治疗。比较3组患者的治疗效果。结果:观察组(A组)与对照组(B、C组)幽门螺杆菌根除率分别是93.62%、83.33%、91.67%;幽门螺杆菌症状缓解率分别是93.62%、89.58%、91.67%;幽门螺杆菌症溃疡愈合率分别是91.49%、87.5%、89.58%,3组比较差异有统计学意义(P<0.05)。结论:雷贝拉唑、克拉霉素、阿莫西林、胶体铋剂四联治疗幽门螺杆菌感染慢性胃炎的治疗效果明显,治愈率、缓解率、溃疡愈合率都相对较高,值得临床广泛应用。
Objective: To investigate the therapeutic effect of rabeprazole, clarithromycin, amoxicillin and colloidal bismuth in the treatment of chronic gastritis with Helicobacter pylori infection. Methods: A total of 143 patients with Helicobacter pylori infection of chronic gastritis who were admitted to our hospital from November 2014 to November 2015 were selected. They were randomly divided into observation group (group A) 47 cases, control group (group B 48 cases) and control group (group C 48 cases). The observation group (group A) received rabeprazole, clarithromycin, amoxicillin, colloidal bismuth quadruple therapy; the control group (group B) was given colloidal bismuth, clarithromycin, amoxicillin triple therapy; (C group) given rabeprazole, clarithromycin, amoxicillin triple therapy. Compare the treatment effect of 3 groups of patients. Results: The H. pylori eradication rates in the observation group (group A) and the control group (group B and C) were 93.62%, 83.33% and 91.67%, respectively. The rates of Helicobacter pylori eradication were 93.62%, 89.58% and 91.67%, respectively. Helicobacter pylori ulcer healing rate was 91.49%, 87.5%, 89.58%, respectively, the difference between the three groups was statistically significant (P <0.05). Conclusion: Rabelazole, clarithromycin, amoxicillin, colloidal bismuth quadruple treatment of Helicobacter pylori infection in chronic gastritis treatment effect is obvious, the cure rate, remission rate, ulcer healing rate is relatively high, it is widely used in clinical .